J Korean Med Sci.  2008 Aug;23(4):678-684. 10.3346/jkms.2008.23.4.678.

The Interaction of Gabapentin and N(6)-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on Mechanical Allodynia in Rats with a Spinal Nerve Ligation

• Park JY
• Jun IG

• KMID: 1785829
• DOI: http://doi.org/10.3346/jkms.2008.23.4.678

Abstract

We examined the antiallodynic interaction between gabapentin and adenosine A1 receptor agonist, N(6)-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA), in a rat model of nerve ligation injury. Rats were prepared with ligation of left L5-6 spinal nerves and intrathecal catheter implantation for drug administration. Mechanical allodynia was measured by applying von Frey filaments. Gabapentin and R-PIA were administered to obtain the dose-response curve and the 50% effective dose (ED50). Fractions of ED50s were administered concurrently to establish the ED50 of the drug combination. The drug interaction between gabapentin and R-PIA was analyzed using the isobolographic method. Adenosine A1 receptor antagonist was administered intrathecally to examine the reversal of the antiallodynic effect. Locomotor function changes were evaluated by rotarod testing. Intrathecal gabapentin and R-PIA and their combination produced a dose-dependent antagonism against mechanical allodynia without severe side effects. Intrathecal gabapentin synergistically enhanced the antiallodynic effect of R-PIA when coadministered. There were no significant changes in rotarod performance time, except gabapentin 300 microgram. In the combination group, the maximal antiallodynic effect was reversed by A1 adenosine receptor antagonist. These results suggest that activation of adenosine A1 receptors at the spinal level is required for the synergistic interaction on the mechanical allodynia.

Keyword

Adenosine; Drug Interactions; Gabapentin; Pain

MeSH Terms

Adenosine/administration & dosage/*analogs & derivatives
Amines/*administration & dosage
Animals
Cyclohexanecarboxylic Acids/*administration & dosage
Dose-Response Relationship, Drug
Drug Synergism
Drug Therapy, Combination
Injections, Spinal
Ligation
Male
Pain/*drug therapy
Rats
Rats, Sprague-Dawley
Receptor, Adenosine A1/drug effects/physiology
Spinal Nerves/*injuries
Xanthines/pharmacology
gamma-Aminobutyric Acid/*administration & dosage

Figure

• 

  Fig. 1 Dose-response curves from the peak effects of percent maximal possible effect (%MPE) for antiallodynia in the gabapentin, N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA), and gabapentin plus R-PIA groups. These curves show a dose-dependent antiallodynic effect. Data are expressed as mean±SEM. Doses (μg) are represented logarithmically on the x axis and peak %MPE is represented on the y axis. Asterisks indicate that the mean %MPE of each group is significant compared with the smallest dose. *p<0.05; unpaired t-test. I.T., intrathecal injection.

• 

  Fig. 2 Time course of antiallodynic effects by intrathecal injection of gabapentin (A), N6-(2-phenylisopropyl)-adenosine R-(-) isomer (R-PIA) (B), and gabapentin plus R-PIA (C). These curves show a dose-dependent antiallodynic effect in each group. Data are expressed as mean±SEM. Asterisks indicate that mean percent maximal possible effect (%MPE) of each group for antiallodynia at that time point is significant compared with baseline value. *p<0.05; one-way repeated-measures analysis of variance followed by multiple comparisons (Tukey's method). I.T., intrathecal injection.

• 

  Fig. 3 Isobologram for the intrathecal interaction of gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA). Horizontal and vertical bars indicate SEM. The diagonal line connecting both 50% effective dose (ED50) points is the theoretical additive line. The ED50 point A is calculated from the ED50 values and 95% confidence intervals of each drug. The experimental ED50 point B lies far below the line of additivity, indicating significant synergism.

• 

  Fig. 4 Antagonism by 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) pretreatment. Pretreatment with DPCPX 10 μg was performed 15 min before injection of a large dose in the gabapentin plus N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) group. Graphs show the time course of the antiallodynic effect in the combination group and pretreatment groups. Data are expressed as mean ±SEM. Maximal antagonism is seen after 30 and 45 min. Asterisks indicate that mean percent maximal possible effect (%MPE) of pretreatment groups for antiallodynia at that time point is significantly less compared with the gabapentin plus R-PIA group. *p<0.05; unpaired t-test. I.T.; intrathecal injection.

• 

  Fig. 5 Effects of intrathecal injection of gabapentin, N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA), and gabapentin plus R-PIA on rotarod performance time. Rotarod performance time was measured before (baseline) and after drug administration. Rotarod performance time was not reduced by administration of gabapentin 100 μg and R-PIA 3, 10 μg, and gabapentin 5 μg plus R-PIA 0.1 μg. Rotarod performance time was significantly decreased at 20 and 60 min after the injection of gabapentin 300 μg. The results are expressed as the mean±SEM. *p<0.05 vs. baseline group by repeated-measures analysis of variance and Tukey's method. I.T., intrathecal injection.

Reference

1. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992. 50:355–363.

2. Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp Brain Res. 1997. 113:200–206.

3. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998. 50:413–492.

4. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol. 1998. 347:1–11.

5. Sawynok J. Purines in pain management. Curr Opin CPNS Invest Drugs. 1999. 1:27–38.

6. Klotz KN. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000. 362:382–391.

7. Lee YW, Yaksh TL. Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. J Pharmacol Exp Ther. 1996. 277:1642–1648.

8. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR. Injury type-Specific calcium channel α₂δ-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002. 303:1199–1205.

9. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997. 121:1513–1522.

10. Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000. 91:185–191.

11. Matthews EA, Dickenson AH. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002. 96:633–640.

12. Gilron I, Biederman J, Jhamandas K, Hong M. Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests. Anesthesiology. 2003. 98:1288–1292.

13. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003. 60:1524–1534.

14. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 1976. 17:1031–1036.

15. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994. 53:55–63.

16. Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 1989. 45:947–961.

17. Cui JG, Sollevi A, Linderoth B, Meyerson BA. Adenosine receptor activation suppresses tactile hypersensitivity and potentiates spinal cord stimulation in mononeuropathic rats. Neurosci Lett. 1997. 223:173–176.

18. von Heijne M, Hao JX, Sollevi A, Xu XJ, Wiesenfeld-Hallin Z. Marked enhancement of anti-allodynic effect by combined intrathecal administration of the adenosine A1-receptor agonist R-phenylisopropyladenosine and morphine in a rat model of central pain. Acta Anaesthesiol Scand. 2000. 44:665–671.

19. Sosnowski M, Yaksh TL. Role of spinal adenosine receptors in modulating the hyperesthesia produced by spinal glycine receptor antagonism. Anesth Analg. 1989. 69:587–592.

20. Choca JI, Proudfit HK, Green RD. Identification of A1 and A2 adenosine receptors in the rat spinal cord. J Pharmacol Exp Ther. 1987. 242:905–910.

21. Bantel C, Tobin JR, Li X, Childers SR, Chen SR, Eisenach JC. Intrathecal adenosine following spinal nerve ligation in rat: short residence time in cerebrospinal fluid and no change in A(1) receptor binding. Anesthesiology. 2002. 96:103–108.

22. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998. 29:233–249.

23. Yoon MH, Yaksh TL. The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. Anesth Analg. 1999. 89:434–439.

24. Matthews EA, Dickenson AH. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002. 96:633–640.

25. Chapman V, Suzuki R, Chamarette HL, Rygh LJ, Dickenson AH. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain. 1998. 75:261–272.

26. Petroff OA, Hyder F, Rothman DL, Mattson RH. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia. 2000. 41:675–680.

27. Su TZ, Lunney E, Campbell G, Oxender DL. Transport of gabapentin, a gamma-amino acid drug, by system L alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem. 1995. 64:2125–2131.

28. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain. 2000. 85:405–414.

29. Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol. 2001. 134:237–240.

30. Leem JW, Choi EJ, Park ES, Paik KS. N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor antagonists differentially suppress dorsal horn neuron responses to mechanical stimuli in rats with peripheral nerve injury. Neurosci Lett. 1996. 211:37–40.

31. Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca²⁺ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol. 2000. 130:900–906.

32. Hwang JH, Hwang GS, Cho SK, Han SM. Morphine can enhance the antiallodynic effect of intrathecal R-PIA in rats with nerve ligation injury. Anesth Analg. 2005. 100:461–468.